Bush tax cut "will halt Medicare Rx benefit"

12 March 2001

Implementation of US President George W Bush's $1,600 billion tax cutwill prevent Congress passing a meaningful Medicare seniors' prescription drug benefit, warns a report by the Democrat policy panel.

Many Democrats felt that the March 8 vote on the tax cut was pushed through too quickly with insuficient debate, reports Reuters. Senator Edward Kennedy, speaking at the launch of the Committee report, said the vote had been about "whether we are going to have a prescription drug benefit or not," while the chairman of the Democratic Policy Council, Senator Byron Dorgen, felt the tax cut "crowds out Medicare prescription drugs and other important priorities."

Meantime, Health and Human Services Secretary Tommy Thompson has been vigorously promoting Pres Bush's interim Immediate Helping Hand prescription drug proposal (Marketletter March 12), stating that Medicare no longer meets the needs of seniors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight